Abstract: The present invention relates to a compound according to formula (I) Formula (I) a physiologically acceptable salt, a solvate, or a hydrate thereof for use in the prevention and/or treatment of diseases caused by betacorona-virus infection in a mammalian subject, such as a human, wherein said compound is administered by inhalation as a pharmaceutical composition comprising preferably alcohol as a carrier. A preferred example is viral infection caused by SARS.

Abstract: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

Abstract: Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The sodium/calcium exchanger is an important mechanism for removing Ca2+ from diverse cells. In heart, it extrudes Ca2+ that has entered through Ca2+ Channels to initiate contraction, while Na+ enters the heart cell. It is of considerable interest to identify Compounds that modulate the activity of sodium/calcium exchangers. The present invention is directed to a fluorescence-based assay for detecting NCX and NCKX “forward mode” modulating Compounds. It further refers to a kit of parts comprising cells expriming a sodium/calcium exchanger and the use of the kit of parts to test a Compound for activity as an agonist or antagonist of a sodium/calcium exchanger.

Abstract: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

Abstract: Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The Sodium/Calcium exchanger is an important mechanism for removing Ca2+ from diverse cells. In heart, it extrudes Ca2+ that has entered through Ca2+ channels to initiate contraction, while Na+ enters the heart cell. It is of considerable interest to identify compounds that modulate the activity of Sodium/Calcium exchangers. The present invention is directed to a fluorescence-based assay for detecting NCX “forward mode” modulating compounds. It further refers to a kit of parts comprising cells expriming NCX and the use of the kit of parts to test a compound for activity as an agonist or antagonist of NCX.

Abstract: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.

Abstract: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke.